Last reviewed · How we verify

NCT06740721: FLAGSHIP_FRA

False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study (FLAGSHIP_FRA)

Not yet recruiting NA Last updated 29 January 2026
What this trial tests

NA trial testing False Lumen Embolization System, IMPEDE-FX RapidFill in Aortic Dissection in 15 participants. Not yet recruiting.

Timeline
1 October 2026
Primary endpoint
4 January 2027
3 January 2029

Quick facts

Lead sponsorShape Memory Medical, Inc.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date1 October 2026
Primary completion4 January 2027
Estimated completion3 January 2029

Drugs / interventions tested

Conditions studied

Sponsor

Shape Memory Medical, Inc. — full company profile →

Who can join

18 and older, any sex, with Aortic Dissection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the safety and feasibility of investigational product to reduce aortic dissection false lumen perfusion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Body-responsive shape-memory polymers for biomedical applications.
    Tajik E, Reihani N, Karamzadeh V, Tang G, et al · · 2026 · PMID 41657946 · DOI 10.1016/j.bioactmat.2025.12.054

Verify or expand the search:

Other trials of False Lumen Embolization System, IMPEDE-FX RapidFill

Trials testing the same drug.

Other recruiting trials for Aortic Dissection

Currently open trials in the same condition.

Other Shape Memory Medical, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing